July 2008
Mayo Clinic Proceedings;Jul2008, Vol. 83 Issue 7, p851
Academic Journal
Correction notice
Corrections to the articles "Urine Drug Screening: Practical Guide for Clinicians" published in the January issue and "Periprocedural Anticoagulation Management of Patients With Nonvalvular Atrial Fibrillation" published in the June 2008 issue are presented.


Related Articles

  • Anticoagulants and Atrial Fibrillation. Rasekh, Abdi // Texas Heart Institute Journal;2005, Vol. 32 Issue 2, p218 

    Discusses the incidence of atrial fibrillation in the U.S. Forecast on the increase in the number of U.S. people with atrial fibrillation; Risk factors for stroke in patients with atrial fibrillation; Treatment of atrial fibrillation.

  • AF imposes significant cost burden. Haimovitch, Larry // Medical Device Daily;5/12/2011, Vol. 15 Issue 92, p6 

    The article offers information on a study on the costs associated with atrial fibrillation.

  • Current strategies in the management of atrial fibrillation.  // Pulse;8/11/2003, Vol. 63 Issue 32, p28 

    Discusses strategies in the management of atrial fibrillation. Association of atrial fibrillation with significant morbidity and mortality; Limitation on the treatment options for the disease; Reduction in cardiac output due to loss of normal atrioventricular synchrony and rapid irregular...

  • Atrial Fibrillation Highlighted in Report, Warfarin Study.  // Journal of Gerontological Nursing;Nov2009, Vol. 35 Issue 11, p8 

    The article discusses the study AF Stat Call to Action for Atrial Fibrillation conducted by Kaiser Permanente and Massachusetts General Hospital researchers in the U.S. The study aims to reduce the burden of atrial fibrillation (AFib) and focuses on issues regarding the management of AFib. It...

  • Practical management of patients on apixaban: a consensus guide. Ward, Christopher; Conner, Greg; Donnan, Geoffrey; Gallus, Alexander; McRae, Simon // Thrombosis Journal;2013, Vol. 11 Issue 1, p27 

    Background Atrial fibrillation (AF) is a common tachyarrhythmia in Australia, with a prevalence over 10% in older patients. AF is the leading preventable cause of ischaemic stroke, and strokes due to AF have a higher mortality and morbidity. Stroke prevention is therefore a key management...

  • Anterior-posterior electrode position led to more cardioversion success in atrial fibrillation. Kirchhof, P.; Eckardt, L.; Loh, P.; Newman, David // ACP Journal Club;May/Jun2003, Vol. 138 Issue 3, p61 

    Summarizes a study that examined whether anterior-posterior electrode position improves cardioversion success in patients with persistent atrial fibrillation. Characterization of the patients; Main results of the study; Link between pressure increases and lower atrial defibrillation.

  • Open-access approach for atrial fibrillation. Izzat, Lena // British Journal of Cardiac Nursing;Jun2012, Vol. 7 Issue 6, p282 

    The author discusses the rationale behind the launch of a formal multidisciplinary atrial fibrillation (AF) assessment clinic in southwest Wales. The clinic provides patients with a clear classification of their AF and a complete stroke risk assessment. The clinic offers open access to all...

  • Burden of disease from atrial fibrillation in adults from seven countries in Latin America. Cubillos, Luz; Haddad, Alexandra; Kuznik, Andreas; Mould-Quevedo, Joaquin // International Journal of General Medicine;2014, Vol. 7, p441 

    Background: While some international studies have published epidemiologic overviewsof atrial fibrillation (AF) for the Latin America region, detailed data at the national level arelacking. The aim of this study was to estimate the burden of disease and morbidity associatedwith AF in adults over...

  • Which NOAC is best alternative to warfarin in AF stroke prevention?  // PharmacoEconomics & Outcomes News;Apr2014, Vol. 701 Issue 1, p8 

    The article discusses an analysis conducted in Norway from the perspective of the Norwegian publicly financed healthcare system on which new oral anticoagulant (NOAC) including dabigatran, apixaban and warfarin is the most effective and cost effective for patients with atrial fibrillation (AF).


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics